Stock listing
NASDAQ:ANL Adlai Nortye Group Ltd. Stock
Follow Adlai Nortye Group Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:ANL
$8.55 USD -0.19 (-2.2%)
Close on Nov 20, 2026
- Day range
- $8.36 – $9.11 USDNov 20, 2026
- Volume
- 380,645 sharesNov 20, 2026
- Market cap
- $502.2M USDAt the close on Nov 20, 2026 · price × 58.73M shares outstanding
- 52-week range
- $0.879 – $17.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.02M USDMedian day 171,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.55 | -0.19 | -2.2% | $8.93 | $9.11 | $8.36 | 380,645 | |
| $8.74 | -0.74 | -7.8% | $9.45 | $9.64 | $8.52 | 454,919 | |
| $9.48 | -0.55 | -5.5% | $9.99 | $9.99 | $9.375 | 291,789 | |
| $10.03 | -0.58 | -5.5% | $10.60 | $11.00 | $9.79 | 172,076 | |
| $10.61 | +0.09 | +0.9% | $10.52 | $10.84 | $9.91 | 152,056 | |
| $10.52 | -0.33 | -3.0% | $10.62 | $10.79 | $10.22 | 130,644 | |
| $10.85 | +0.89 | +8.9% | $10.03 | $11.21 | $9.76 | 195,930 | |
| $9.96 | -1.19 | -10.7% | $10.98 | $11.15 | $9.46 | 377,005 | |
| $11.15 | +0.87 | +8.5% | $9.85 | $11.45 | $9.85 | 263,352 | |
| $10.28 | +0.60 | +6.2% | $9.77 | $10.64 | $9.43 | 531,007 | |
| $9.68 | +0.07 | +0.7% | $9.61 | $9.85 | $8.90 | 450,319 | |
| $9.61 | +0.03 | +0.3% | $9.70 | $10.06 | $9.075 | 238,622 | |
| $9.58 | +0.21 | +2.2% | $9.39 | $9.925 | $9.39 | 236,053 | |
| $9.37 | -0.18 | -1.9% | $9.75 | $9.89 | $9.21 | 272,626 | |
| $9.55 | -0.73 | -7.1% | $10.11 | $10.13 | $9.36 | 262,097 | |
| $10.28 | +0.08 | +0.8% | $10.20 | $10.68 | $10.20 | 44,559 | |
| $10.20 | -0.51 | -4.8% | $11.10 | $11.10 | $10.04 | 125,334 | |
| $10.71 | +0.13 | +1.2% | $10.68 | $11.10 | $10.68 | 71,157 | |
| $10.58 | 0.00 | 0.0% | $10.71 | $10.85 | $10.52 | 132,919 | |
| $10.58 | 0.00 | 0.0% | $10.55 | $10.65 | $10.30 | 79,500 | |
| $10.58 | -0.68 | -6.0% | $11.01 | $11.22 | $10.58 | 170,000 | |
| $11.26 | +0.62 | +5.8% | $10.80 | $11.68 | $10.80 | 532,600 | |
| $10.64 | +0.26 | +2.5% | $10.37 | $11.32 | $10.37 | 242,600 | |
| $10.38 | -0.65 | -5.9% | $10.97 | $11.38 | $10.34 | 356,500 | |
| $11.03 | -1.06 | -8.8% | $11.89 | $12.04 | $10.93 | 336,600 | |
| $12.09 | +1.21 | +11.1% | $11.23 | $12.46 | $11.23 | 864,200 | |
| $10.88 | -0.875 | -7.4% | $11.88 | $12.11 | $10.80 | 378,000 | |
| $11.76 | -2.465 | -17.3% | $14.20 | $14.20 | $11.40 | 957,700 | |
| $14.22 | -1.40 | -9.0% | $15.65 | $16.22 | $13.91 | 415,700 | |
| $15.62 | +0.11 | +0.7% | $15.33 | $16.74 | $14.87 | 300,400 | |
| $15.51 | +1.46 | +10.4% | $13.87 | $16.05 | $13.78 | 985,300 | |
| $14.05 | -0.41 | -2.8% | $14.41 | $15.04 | $14.03 | 95,100 | |
| $14.46 | -0.58 | -3.9% | $15.03 | $15.68 | $14.23 | 99,800 | |
| $15.04 | -0.05 | -0.3% | $14.80 | $15.82 | $14.34 | 460,600 | |
| $15.09 | -0.67 | -4.3% | $15.76 | $15.80 | $14.83 | 77,000 | |
| $15.76 | -0.24 | -1.5% | $16.00 | $16.20 | $15.54 | 124,800 | |
| $16.00 | +0.35 | +2.2% | $15.87 | $16.31 | $15.50 | 93,900 | |
| $15.65 | +0.25 | +1.6% | $15.26 | $15.82 | $15.11 | 63,000 | |
| $15.40 | -0.13 | -0.8% | $15.70 | $15.86 | $15.10 | 63,500 | |
| $15.53 | -0.30 | -1.9% | $16.16 | $16.16 | $15.38 | 34,800 | |
| $15.83 | +0.08 | +0.5% | $15.51 | $16.05 | $14.70 | 144,300 | |
| $15.75 | -0.85 | -5.1% | $16.47 | $16.95 | $15.60 | 218,100 | |
| $16.60 | +1.03 | +6.6% | $15.80 | $16.73 | $15.66 | 105,200 | |
| $15.57 | -0.17 | -1.1% | $15.99 | $16.16 | $15.05 | 92,600 | |
| $15.74 | +0.46 | +3.0% | $15.13 | $15.92 | $15.13 | 156,600 | |
| $15.28 | -0.24 | -1.5% | $15.89 | $16.25 | $15.00 | 91,500 | |
| $15.52 | +0.52 | +3.5% | $15.16 | $15.75 | $14.93 | 220,800 | |
| $15.00 | -0.93 | -5.8% | $15.92 | $16.19 | $14.87 | 171,300 | |
| $15.93 | +0.72 | +4.7% | $15.18 | $16.10 | $15.13 | 175,600 | |
| $15.21 | +0.12 | +0.8% | $15.32 | $16.00 | $15.20 | 228,700 | |
| $15.09 | +0.395 | +2.7% | $14.97 | $15.78 | $14.70 | 318,200 | |
| $14.70 | -0.815 | -5.3% | $15.44 | $15.94 | $14.42 | 161,800 | |
| $15.51 | +0.50 | +3.3% | $15.12 | $16.12 | $14.82 | 405,000 | |
| $15.01 | +0.26 | +1.8% | $14.69 | $16.02 | $14.55 | 308,600 | |
| $14.75 | +0.895 | +6.5% | $13.95 | $14.79 | $13.78 | 77,000 | |
| $13.86 | +0.225 | +1.7% | $13.76 | $14.20 | $13.48 | 77,700 | |
| $13.63 | -0.56 | -3.9% | $14.02 | $14.41 | $13.32 | 104,400 | |
| $14.19 | +0.37 | +2.7% | $13.84 | $14.44 | $13.26 | 139,200 | |
| $13.82 | -0.50 | -3.5% | $14.41 | $14.46 | $13.53 | 165,000 | |
| $14.32 | -0.74 | -4.9% | $14.88 | $15.20 | $14.05 | 137,000 | |
| $15.06 | +1.32 | +9.6% | $13.70 | $15.11 | $13.50 | 147,800 | |
| $13.74 | -0.42 | -3.0% | $14.09 | $14.29 | $13.55 | 100,200 | |
| $14.16 | +0.46 | +3.4% | $13.66 | $14.40 | $13.14 | 185,800 | |
| $13.70 | -0.02 | -0.1% | $13.97 | $14.28 | $13.52 | 103,100 | |
| $13.72 | -0.61 | -4.3% | $14.30 | $14.30 | $13.56 | 117,200 |
- Ticker
- NASDAQ:ANL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 27, 2026
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 43 slides
Latest news
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Oct 27, 2026
Closed $10.20 (-4.8%) on Oct 28, 2026
Adlai Nortye Group Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Oct 27, 2026 · oldest 2026
- Decks
- 4 decks · latest September 2026
Valuation
EV/sales 59.4× against a median of 13.1×: the highest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $297.0M USD
- P/E
- Loss
- EV/sales
- 59.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- 100.0%
- Operating margin
- −714.0%
- Net margin
- −710.6%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.96
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.0M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$497.0M | US$470.5M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.6M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Median of the others | US$496.1M | US$258.5M | 13.1× | 2.0× | −248.8% | 0.1× | 1.60 |
Forecasts
7 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.18 · 7 analysts
- Revenue, year to Dec 2026
- 17.19M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Yang Lu | CEO, Chairman of the Board of Directors |
| Xiaofeng Ye | Chief Financial Officer |
| Archie Tse | President, Head of R&D |
| Christopher Liu | Head of Investor Relations and Public Relations |
| Nanhai He | Head of Discovery |
| Zhiyong Yu | Head of Operation |
Board
| Director | Role |
|---|---|
| Yang Lu | CEO, Chairman of the Board of Directors |
| Baozhong Wei | Independent Director |
| Lars E. Birgerson | Director |
| Ming Lun Alan Tse | Independent Director |
| Ping Ji | Director |
| Roger Sawhney | Independent Director |
| Shaorong Liu | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Feb 25, 2026 | −9.2% |
| Q3 2025 | Dec 3, 2025 | −17.2% |
| Q2 2025 | Aug 7, 2025 | +0.7% |
| Q1 2025 | Apr 30, 2025 | +1.0% |
| Q3 2024 | Nov 27, 2024 | +2.8% |
| Q2 2024 | Aug 8, 2024 | +6.7% |
| Q4 2023 | Feb 28, 2024 | 0.0% |
| Q3 2023 | Nov 29, 2023 | +4.1% |
| Q2 2023 | Aug 30, 2023 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 43 slides | September 2026 |
| Investor Presentation (April 2026) | Investor deck | 30 slides | Apr 16, 2026 |
| AACR-NCI-EORTC 2025 | Conference | 11 slides | Oct 25, 2025 |
| Investor Presentation (May 2024) | Investor deck | 31 slides | May 24, 2024 |
IPO
Went public as Adlai Nortye Ltd. Priced at US$23.00 an ADS on Sep 29, 2023.
- Price
- US$23.00 an ADS
- ADSs offered
- 2,500,000 American depositary shares
- Offering size
- US$57.5 million
- Listing
- ANL on the Nasdaq Global Market
- Underwriter
- Cantor
- ADSs delivered
- On or about Oct 3, 2023
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 21, 2022 |
| Filed publicly | Jul 27, 2023 |
| Amended 4 times | Newest Sep 27, 2023 |
| Shares registered with an exchange | Aug 7, 2023 |
| Declared effective by the SEC | Sep 28, 2023 |
| Final prospectus, with the price | Sep 29, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 29, 2023 |
| EFFECT · Notice that a registration is effective | Sep 28, 2023 |
| CERT · Exchange's certificate of listing | Sep 28, 2023 |
| CORRESP · Letter to the SEC | Sep 27, 2023 |
| CORRESP · Letter to the SEC | Sep 27, 2023 |
| CORRESP · Letter to the SEC | Sep 27, 2023 |
| F-1/A · Registration statement, amended | Sep 27, 2023 |
| UPLOAD · Letter from the SEC | Sep 20, 2023 |
| CORRESP · Letter to the SEC | Sep 12, 2023 |
| F-1/A · Registration statement, amended | Sep 12, 2023 |
All 34 filings
Open IPO · From the cover of the final prospectus (424B4) filed Sep 29, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.00M | 0 | 5.00M | 0 | 45.7M | ||
| Cost of revenue | 1.87M | 2.22M | 2.04M | 1.51M | 1.48M | ||
| Gross profit | 5.00M | -1.87M | 5.00M | -2.04M | 45.7M | -1.51M | -1.48M |
| Research and development | 32.8M | 44.9M | 58.2M | 54.5M | 42.1M | 19.0M | 13.3M |
| Selling, general and administrative | 7.79M | 9.44M | 14.8M | 12.4M | 12.4M | 6.52M | |
| Operating income | -35.7M | -52.9M | -72.6M | -67.3M | -8.65M | -26.1M | -19.1M |
| Depreciation and amortization | 1.41M | 510.0K | 465.0K | 609.0K | 861.0K | 1.51M | 1.48M |
| EBITDA | -34.3M | -52.4M | -72.1M | -66.7M | -7.79M | -24.6M | -17.6M |
| Interest expense | 1.49M | 1.94M | 791.0K | 433.0K | 1.34M | 1.75M | 466.1K |
| Income before tax | -35.5M | -51.9M | -109.2M | -58.8M | -56.7M | -63.4M | -17.8M |
| Income tax | 643.0K | 8.31M | -46.2M | 3 | -1 | ||
| Net income | -35.5M | -51.9M | -109.2M | -58.8M | -56.7M | -63.4M | -17.8M |
| Earnings per share, basic | -3.33 | -0.54 | -2.52 | -2.31 | -2.23 | -7.47 | -2.10 |
| Earnings per share, diluted | -0.54 | -2.52 | -2.31 | -2.23 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 23.8M | 60.9M | 91.5M | 42.8M | 64.1M | 24.2M | 6.02M |
| Short-term investments | 0 | 7.00K | 7.01M | 21.3M | 53.8M | 241.0K | |
| Receivables | 1.39M | 1.17M | 359.0K | 346.0K | 1.93M | 394.0K | 91.6K |
| Inventory | 1 | -3 | 100 | 1 | 1 | ||
| Current assets | 26.9M | 64.1M | 101.2M | 66.3M | 124.5M | 28.6M | 6.43M |
| Property, plant and equipment | 1.74M | 2.65M | 3.71M | 3.65M | |||
| Total assets | 34.4M | 71.3M | 130.2M | 72.6M | 131.7M | 36.7M | 10.8M |
| Accounts payable | 12.6M | 10.1M | 14.3M | 13.1M | 2.98M | 1.53M | 5.26M |
| Current liabilities | 41.6M | 45.4M | 49.7M | 312.7M | 17.5M | 88.0M | 20.3M |
| Total debt | 26.4M | 26.3M | 30.4M | 4.31M | 10.5M | 11.0M | 11.9M |
| Total liabilities | 42.8M | 45.8M | 55.1M | 313.9M | 317.1M | 168.3M | 80.2M |
| Shareholders' equity | -8.32M | 25.5M | 75.0M | -241.3M | -185.4M | -131.6M | -69.4M |
| Shares outstanding | 10.7M | 10.6M | 6.80M | 40.4M | 12.3M | 8.48M | 8.48M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -33.5M | -51.8M | -56.7M | -43.2M | -3.03M | -34.6M | -14.9M |
| Capital spending | -187.5K | -170.0K | -200.0K | -1.25M | -1.02M | -1.62M | -185.0K |
| Free cash flow | -33.7M | -52.0M | -56.9M | -44.5M | -4.05M | -36.2M | -15.1M |
| Cash from investing | -15.6M | 28.1M | -11.0M | 28.4M | -54.9M | -1.61M | -184.5K |
| Cash from financing | -3.82M | -6.58M | 116.2M | -6.78M | 97.2M | 53.9M | 16.2M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | ||
| Change in cash | -37.1M | -30.3M | 48.6M | -21.6M | 39.3M | 18.2M | 1.11M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 18, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 16, 2026 | Other filings | SEC |
| S-8 POS | Sep 11, 2026 | Offer document | SEC |
| S-8 POS | Sep 11, 2026 | Offer document | SEC |
All 114 filings
Cap table
Built by 6ix from Adlai Nortye Group Ltd.’s releases
- Common shares
- 58,734,603
- Fully diluted
- 58,734,603
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 58,734,603 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 58,734,603 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Roger Sawhney Other companies: Arbutus Biopharma Corporation (Director · Since at least Aug 4, 2025); Actuate Therapeutics, Inc. (Director · Since at least Aug 12, 2024); Alimera Sciences Inc (Director · Feb 25, 2023 – Feb 25, 2023 · Past); Omega Therapeutics Inc (Chief Financial Officer · Jul 29, 2021 – Mar 9, 2022 · Past) | Independent Director · Since at least Mar 18, 2026 |
| Alan Ming Lun Tse | Director · Since at least Mar 18, 2026 |
| Archie Tse | President, Head of R&D · Since at least Mar 18, 2026 |
| Baozhong Wei | Independent Director · Since at least Nov 5, 2026 |
| Christopher Liu | Head of Investor Relations and Public Relations · Since at least Nov 5, 2026 |
| Kaiyang Tang | President, Adlai Nortye USA · Since at least Mar 18, 2026 |
| Lars E. Birgerson | Director · Since at least Mar 18, 2026 |
| Ming Lun Alan Tse | Independent Director · Since at least Nov 5, 2026 |
| Nanhai He | Head of Discovery · Since at least Nov 5, 2026 |
| Ping Ji | Director · Since at least Mar 18, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Shaorong Liu | Independent Director · Since at least Nov 5, 2026 |
| Xiaofeng Ye | CFO · Since at least May 28, 2026 |
| Yang Lu | CEO, Director · Since at least Mar 18, 2026 |
| Zhiyong Yu | Head of Operation · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Adlai Nortye Group Ltd.